1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209-249.
2. Berdik C. Unlocking bladder cancer. Nature 2017; 551:S34-s35.
3. Suprynowicz FA, Upadhyay G, Krawczyk E, Kramer SC, Hebert JD, Liu X, et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 2012; 109:20035-20040.
4. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-1431.
5. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9:338-350.
6. Fiebig HH, Schuchhardt C, Henss H, Fiedler L, Löhr GW. Comparison of tumor response in nude mice and in the patients. Behring Inst Mitt 1984:343-352.
7. Shorthouse AJ, Smyth JF, Steel GG, Ellison M, Mills J, Peckham MJ. The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg 1980; 67:715-722.
8. Suh YS, Jeong K-C, Lee S-J, Seo HK. Establishment and application of bladder cancer patient-derived xenografts as a novel preclinical platform. Transl Cancer Res 2017:S733-S743.
9. Williams JA. Using PDX for preclinical cancer drug discovery: The evolving field. J Clin Med 2018; 7.
10. Bernardo C, Costa C, Sousa N, Amado F, Santos L. Patient-derived bladder cancer xenografts: a systematic review. Transl Res 2015; 166:324-331.
11. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002; 100:3175-3182.
12. Chijiwa T, Kawai K, Noguchi A, Sato H, Hayashi A, Cho H, et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol 2015; 47:61-70.
13. Paez-Ribes M, Man S, Xu P, Kerbel RS. Development of patient derived xenograft models of overt spontaneous breast cancer metastasis: A cautionary note. PLoS One 2016; 11:e0158034.
14. Razzaghdoust A, Ghajari M, Basiri A, Mohammadi Torbati P, Jafari A, Fattahi MR, et al. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer. Investig Clin Urol 2021; 62: 274-281.
15. Simon R. Tissue microarrays: methods and protocols: Wiley Online Library; 2010.
16. Mondal AM, Ma AH, Li G, Krawczyk E, Yuan R, Lu J, et al. Fidelity of a PDX-CR model for bladder cancer. Biochem Biophys Res Commun 2019; 517:49-56.
17. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget 2015; 6:21522-21532.
18. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, et al. Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy. PLoS One 2015; 10:e0134346.
19. Park B, Jeong BC, Choi YL, Kwon GY, Lim JE, Seo SI, et al. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci 2013; 104:631-638.
20. Bernardo C, Santos LL. Patient-derived bladder cancer xenografts. Methods Mol Biol 2018; 1655:169-175.
21. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009; 4:1670-1680.